Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

The largest price increases came from Leadiant Pharmaceuticals, a subsidiary of Italy-based Essetifin. Leadiant raised prices ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive Versant's backing in ...